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WORK AND HEALTH CONDITIONS DURING PREGNANCY IN
WOMEN OF THE MEXICAN SOCIAL SECURITY INSTITUTE
Torres-Arreola LDP1,Villa-Barragán JP2
1Instituto Mexicano del Seguro Social, México D.F, Mexico; 2Instituto
Nacional de Pediatría, México, D.F, Mexico
OBJECTIVES: To compare socio-demographic, reproductive
and prenatal attention conditions among women who perform
work outside the home (as opposed to housework); in the case
of those going out to work, to describe the conditions of such
work; and ﬁnally to show whether health-related differences
exist that correlate with working situation (at home vs. outside
the home). METHODS: Transversal study (pilot) carried out in
a family medicine unit of the Mexican Social Security Institute
(IMSS) between April and July 2003, during which period inter-
views were effected with 537 pregnant women engaged in either
paid work, housework, or both, and registered with the Family
Medicine external consultation services. A questionnaire was
applied in order to establish demographic and reproductive
characteristics, as well as variables related with prenatal control
and the existence of symptoms before and after pregnancy;
ﬁnally, to provide information on characteristics of both domes-
tic and extra-domestic work. RESULTS: In total, 36.5% were
women with paid work (A), the rest having exclusively domes-
tic work (63.5%) (B). Of those with extra-domestic work (A),
78.6% had clerical or similar jobs, mainly in service activities
(45%), and 18.9% were industrial workers. Stress at work is
present in 74% of cases interviewed. On analyzing the effect of
work on women’s health conditions, it was observed that women
who do not go out to work show a higher risk of muscular-skele-
tal alterations than those who do so (RM: 4.3 IC95% 1.6–11.4).
The presence of genitourinary symptoms is greater for those who
claim to have had more than three children and who remain at
home. CONCLUSIONS: The monitoring of domestic work is
important in view of the need for attention to the conditions in
which such work is carried out; it also helps identify potential
risks for health.
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QUALITY OF LIFE AND HEALTH BEHAVIORS OF
VENEZUELAN PHARMACY STUDENTS
Bastardo YM
Central University of Venezuela, Caracas, DC,Venezuela
OBJECTIVES: The purpose of this study was to describe health-
related quality of life (HRQL) of Venezuelan pharmacy students
and to explore the association among quality of life, health
behaviors, and demographics. METHODS: A random sample
171 of pharmacy students, ranging in age from 18 to 35 years
were surveyed using a written questionnaire. HRQL was deter-
minate using the Medical Outcome Study Short Form 36 (MOS
SF-36).The associations among HRQL, demographics, and
health behaviors were examined using both bivariate and multi-
variate models. RESULTS: The sample consisted of 127 females
and 44 males. The sample had a mean age of 22.3 years. As
expected the sample was healthy: only 11 subjects (6.47%) eval-
uated their health as poor and 30 subjects (17.5%) reported to
suffer from an illness. Forty subjects (23.4%) reported current
medication use. The prevalence of alcohol consumption during
the previous month was 65.8% and for smoking it was 15.5%.
One third of the sample reported no exercising during the pre-
vious month. Multiple regression analyses were used to model
HRQL score as a function of age, sex, income, illness, lack of
regular exercise, alcohol consumption, and smoking. The regres-
sion model explained approximately 20% of the variance in
HRQL. Controlling for other variables in the model, low
income, illness, and smoking had a signiﬁcant negative impact
on HRQL. Lack of regular exercise and age were not associated
with HRQL. Controlling for other variables male students had
signiﬁcantly higher scores in HRQL than female students.
Alcohol consumption was associated with HRQL in bivariate
but not in multivariate models. CONCLUSIONS: The overall
quality of life of pharmacy students in Venezuela is good. This
exploratory study demonstrates sex differences in perceived
quality of life of college students. Quality of life is associated to
certain predictors of future health status, including health behav-
iors such as smoking.
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ASSESSING THE PSYCHOMETRIC PROPERTIES OF THE
PSYCHOSOCIAL SUBSCALE OF THE MENOPAUSE-SPECIFIC
QUALIPAUSE INVENTORY (QPI) WITH ITEM RESPONSE
THEORY
Kuessner D1, Zoellner YF2
1University of Magdeburg, Magdeburg, Germany; 2Solvay
Pharmaceuticals GmbH, Hannover, Germany
OBJECTIVES: To analyse the 8-item, 5-level psychosocial sub-
scale of the QualiPause Inventory (QPI)—a recently developed,
condition-speciﬁc health-related quality of life (HRQoL) instru-
ment for peri- and post-menopausal women—with item response
theory (IRT). METHODS: Data: postal survey of 785 women
aged 45–65 years, identiﬁed from Shefﬁeld general practice lists.
Techniques: “Kernel-smoothing-technique” (KST)—in order to
investigate the item-response and test-information curves—
followed by the estimation of Muraki’s general partial credit
model (GPCM). Software: Testgraph and Parscale, respectively.
RESULTS: The non-parametric KST showed that the scale pro-
vides most information for above-average psychosocial distress,
with a peak for subjects with a trait of approximately 1.5 stan-
dard deviations (SDs) above the sample average. Review of cat-
egory response curves suggests that, in order to optimize model
ﬁt: for items 2–5 and 8, response categories 2 (hardly bothered)
and 3 (moderately bothered) should be collapsed; for items 1, 6,
and 7, categories 2 to 4 (considerably bothered) could be col-
lapsed. The GPCM yielded step parameters lying in the range of
-0.818 and 2.082 with respect to the standard normal distribu-
tion and therefore covers the medium-to-severe trait spectrum.
Item 2 (feeling tense) has got the highest slope parameter (2.1),
and item 1 (difﬁculty sleeping) has got the lowest (0.573).
Overall, items 2–5 contribute most information. CONCLU-
SIONS: The psychosocial subscale of the QPI is particularly 
valuable to assess HRQoL of peri- and post-menopausal women
with moderate to severe symptoms of emotional distress. The
results may be used for further developing of the QPI. In 
particular, items 1 and 8 may be candidates for deletion as they
add little extra information. This type of analysis facilitates the
interpretation of patient-reported outcomes and may, therefore,
lead to a higher acceptance of such instruments by decision-
makers.
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OBJECTIVES: To evaluate, in daily practice, the beneﬁts of
drotrecogin alfa (DA) in the treatment of severe septic patients
with multiple organ failure and optimum intensive care support.
METHODS: In this prospective, observational pre-post study,
the clinicians were free to include any patient meeting DA’s inclu-
sion criteria before and after DA’s marketing. An optimal
propensity score matching technique was used to reduce recruit-
ment bias. Survival was modeled using a Cox proportional
hazards model with a shared frailty term to account for the clus-
tering of patients within the intensive care units. The number of
bleeding events measured DA’s safety. RESULTS: Respectively
509 and 587 patients were included in the before and after
groups. There is strong evidence of recruitment bias: patients in
the after group are younger, more frequently ventilated, have less
comorbidities but more organ failures. After propensity score
matching, 840 patients were retained in the analysis, with a
better balance between the groups. The use of a frailty model
improves signiﬁcantly the variance explained by the survival
model, showing a non-negligible cluster effect. When consider-
ing the whole sample of patients, without adjustments, survival
is improved in the after (i.e. with DA) group (p = 2.5%), with a
hazard ratio (HR) of 0.805. In the matched sample, there are 
no signiﬁcant survival differences (HR = 0.900, p = 35.0%).
However, after stratifying by the LODS severity score quartiles,
signiﬁcance is reached (HR = 0.795, p = 4.8%). In the matched
sample, a negative binomial model best described bleeding
events. In this model, patients in the after group have a higher
mean of bleeding events (p = 2.0%). CONCLUSION: This
observational study conﬁrms DA’s clinical trial results in the real
practice setting. However, the use of the propensity score cannot
replace randomization to assure perfect balance for all patient
characteristics, measured and unmeasured. The results should
therefore be considered with caution.
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ECONOMIC IMPLICATION OF HEPATITIS B VIRAL (HBV)
LOAD REDUCTION FOR ENTEVAVIR IN HEPATITIS B E
ANTIGEN-POSITIVE CHRONIC HEPATITIS B (CHB) PATIENTS
Yuan Y1, Iloeje U2, Cross A2, Hay J3
1Bristol-Myers Squibb Company, Plainsboro, NJ, USA; 2Bristol-Myers
Squibb Company, Wallingford, CT, USA; 3University of Southern
California, Los Angeles, CA, USA
OBJECTIVES: To evaluate the cost effectiveness of entecavir in
reducing HBV DNA viral load(VL) and subsequent compensated
cirrhosis (CC), decompensate cirrhosis (DC), and hepatocellular
cancer(HCC). METHODS: The analytic perspective was that of
a third-party payer. We used patient-level drug exposure and VL
data from a randomized phase III trial of 715 HBeAg+ CHB
patients, and estimates of cost offsets and life expectancy gains
as a result of the prevention of projected clinical events. The mul-
tivariate-adjusted relative risks with VL categories were esti-
mated by Cox proportional hazards models from a Taiwan
cohort of 3851 CHB subjects with 42,115 person-years of
follow-up, and then applied to the trial patients whose VL were
measured at Week 48 to estimate event risks. Entecavir and
lamivudine were assigned daily prices of $19.43 and $6.14
respectively, based on recent First Data-Bank reports. Life
expectancy for DC and HCC was estimated by the declining
exponential approximation of life expectancy (DEALE) method.
Other model parameter values were derived from external
sources. The uncertainty surrounding event distribution and
treatment failure rates beyond trial period were considered using
probabilistic sensitivity analyses (PSA) with 1000 replicates.
RESULTS: Subjects were male (75%), Asian (57%) or white
(40%) with mean age 35 years. Entecavir was superior to
lamivudine for the proportion of subjects who achieved HBV
DNA < 300 copies/ml by PCR assay at Week 48 (67% versus
37% , respectively) (P < 0.05). One year of entecavir therapy
gained 0.7843 quality-adjusted life year (QALY) at an incre-
mental cost of $1607, with a 3% annual discount. Compared
with lamivudine, using entecavir cost an incremental $2049 per
QALY gained (95%CI: $688, $5134), with 98.8% of PSA-
derived estimates below $10,000/QALY. Results are robust and
most sensitive to treatment duration, efﬁcacy, and cost. CON-
CLUSIONS: Entecavir given for one year is clinically effective
and highly cost-effective in HBeAg+ patients.
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COST-EFFECTIVENESS ANALYSIS OF COMBINED THERAPY
WITH PEGINTERFERON ALFA 2A (40KD) (PEGASYS®) AND
RIBAVIRIN (COPEGUS®) IN PATIENTS WITH CHRONIC C
HEPATITIS (CHC) AND PERSISTENTLY NORMAL ALT LEVELS
(PNALT)
Rubio Terres C1, Álvarez Sanz C2, Patel KK3
1HERO CONSULTING, Madrid, Madrid, Spain; 2Roche Farma S.A,
Madrid, Madrid, Spain; 3Hoffmann-La Roche, Nutley, NJ, USA
OBJECTIVE: To establish the clinical prognosis, costs and cost-
effectiveness of peginterferon alfa-2a (180mcg/week) plus rib-
avirin versus no treatment in patients with CHC and PNALT
from a Spanish national health care system (NHS) perspective.
METHODS: A Markov model was developed to simulate the
disease progression of 45-year old patients with CHC and
PNALT. Fibrosis progression rates in PNALT were obtained
from published studies. Efﬁcacy, in terms of sustained virologi-
cal response (SVR), for peginterferon alfa-2a plus ribavirin and
no treatment in patients with genotype 1 and genotype 2/3 was
obtained from a multinational, randomized, controlled trial. In
this trial, no patients in the control arm achieved an SVR. Tran-
sition probabilities and quality of life estimates were obtained
from published literature. Unit costs were obtained from a
Spanish database. The discount rate employed was 3.5%.
RESULTS: In genotype 1 patients, peginterferon alfa-2a plus rib-
avirin compared with no treatment increases patients life
expectancy by 0.63 years (0.70 quality-adjusted life years
(QALYs)), yielding an incremental cost-effectiveness ratio
(ICER) of 14,729 €/ life year gained (LYG) (€13,388/QALY). In
genotype 2/3 patients, peginterferon alfa-2a plus ribavirn
increases life expectancy by 1.14 years (1.26 QALYs), yielding
an ICER of 109 €/LYG (99 €/QALY). The overall ICER based
on the genotype distribution in the trial is €11,374/LYG
(€9952/QALY). CONCLUSIONS: From the Spanish NHS per-
spective, peginterferon alfa-2ª (40KD) (PEGASYS®) plus rib-
avirin (COPEGUS®) in patients with CHC and PNALT is a
cost-effective treatment option, regardless of HCV genotype.
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COST-EFFECTIVENESS ANALYSIS OF ALTERNATIVE
ANTIMICROBIAL TREATMENTS FOR COMMUNITY-ACQUIRED
PNEUMONIA (CAP)
Martin M1, Quilici S1, Garau J2, File TM3, Kubin M4
1Innovus Research (UK) Ltd, High Wycombe, UK; 2Hospital Mutua de
Terassa, Barcelona, Spain; 3Summa Health System, Akron, OH, USA;
4Bayer Health care AG, Wuppertal, Germany
OBJECTIVE: To evaluate the cost-effectiveness of the empirical
use of moxiﬂoxacin in community-acquired pneumonia (CAP)
taking into account clinical failure caused by prevailing levels of
antimicrobial resistance in France, Germany and the US repre-
senting high, low and moderate levels of resistance respectively.
METHODS: Only anecdotal evidence is available in the litera-
ture on the direct link between resistance and clinical failure. A
